Answers are grounded in this paper and cite their sources.
Antiviral treatment for SARS-CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2) is still being studied for its effectivity. The antivirals in the July 3, 2021 edition of the COVID-19 management guidelines, namely favipiravir and remdesivir, are used for moderate, severe and critical degrees. The study compares the mortality rate of COVID-19 patients taking the antivirals favipiravir and remdesivir. This research is a retrospective cohort study conducted at RSUP Dr. Sardjito Yogyakarta. The data was from the medical records of patients diagnosed with moderate, severe, and critical degrees of COVID-19 treated during the January-December 2021 period. Ninety-nine patients (50.8%) used favipiravir, while 97 patients (49.5%) used remdesivir. Chi-square analysis and multiple logistic regression were used to determine the relationship between research variables. Study subjects with the highest percentage of age 46-65 years (65%), male sex (54,6%), comorbid diabetes mellitus and hypertension (13,3%), severe degree of severity (60,7%), and viral load CT value ≤ 29 (80,1%), the patient went home alive (61,2%), and died (38,8%). The antivirals did not affect on mortality (p > 0,05). Further research is needed with the same characteristics of the two groups involving factors of degree severity of the disease, co-morbidity, and other medication therapy.
No takes yet. Share an insight, caveat, or question.
Satriyani et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: